TVAX Biomedical, Inc. is a clinical-stage development company advancing its targeted cell-based immunotherapy for the treatment of cancer. The Company offers immunotherapeutic cancer treatment platform for various types of cancers. The Company's lead candidate is TVI-Brain-1, which is used for the treatment of brain cancer and targets glioblastomas. The Company has completed Phase II trials for TVI-Brain-1. The Company's other candidate is TVI-Kidney-1, which is used for the treatment of kidney cancer and targets stage 4 renal cell carcinoma. The Company has completed Phase II trials for TVI-Kidney-1. The Company's immunotherapeutic cancer treatment platform, TVAX Immunotherapy, is a personalized combination of cancer cell vaccination and killer T cell treatment platform. The Company's subsidiary, TVAX Animal Health, is focused on adapting the TVAX Immunotherapy for applications in the veterinary sector with a focus on cancer in dogs.
TVAX BIOM 
